Financial Data and Key Metrics Changes - Income from operations increased by 1.4% in Q1, excluding foreign currency impact, primarily due to gross margin dollar growth within the supply chain and higher international franchise royalties and fees [16] - Global retail sales grew by 4.7% in Q1, driven by positive international comps and global net store growth compared to the previous year [17] - U.S. retail sales grew by 1.3%, primarily driven by net store growth, while same-store sales declined by 0.5% [17][18] - International retail sales grew by 8.2%, excluding foreign currency impact, with same-store sales at 3.7% [20] Business Line Data and Key Metrics Changes - The U.S. carryout business comps were up 1%, while delivery was down 1.5% in the quarter, indicating a shift in consumer preference [18] - The launch of the Parmesan Stuffed Crust Pizza is expected to drive future sales, although it had minimal impact in Q1 due to its late introduction [7][8] Market Data and Key Metrics Changes - The U.S. QSR pizza category was roughly flat to start the year, while Domino's outperformed with a 1.3% growth in retail sales [17][18] - International markets showed strength, particularly in Asia, driven by strong comps in India and Canada [20][21] Company Strategy and Development Direction - The "Hungry for More" strategy focuses on driving sales, store growth, and profits through innovation, operational excellence, and renowned value [5][6] - The company plans to launch at least two new products each year, with the Parmesan Stuffed Crust Pizza being a significant addition [6][7] - A partnership with DoorDash is expected to enhance delivery capabilities, with a national launch anticipated in May [11][12] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenging macro backdrop but expressed confidence in achieving market share gains [5][16] - The company expects U.S. same-store sales to be around 3% for the year, with potential macro pressures impacting this guidance [22][75] - International same-store sales growth is expected to be between 1% to 2%, considering geopolitical and macroeconomic pressures [22][114] Other Important Information - The company repurchased approximately 115,000 shares at an average price of $434, totaling $50 million in Q1 [21] - Organizational changes were made to streamline operations, which included the elevation of key executives [13][14] Q&A Session Summary Question: Impact of geopolitical pressures on international markets - Management noted that geopolitical volatility could impact demand, which is reflected in the guidance of 1% to 2% growth for the year [26][27] Question: Incrementality expectations from DoorDash - Management expects DoorDash to contribute approximately 50% incrementally to sales, with expectations of higher performance compared to Uber Eats [30][31] Question: Performance of the stuffed crust pizza - The stuffed crust pizza has received positive customer feedback, and while it did not significantly impact Q1, it is expected to drive future sales [34][35] Question: Domestic unit growth guidance - The company maintains its guidance of adding 175 net stores in 2025, with franchisee enthusiasm remaining strong [55][56] Question: Carryout customer performance - The carryout business experienced a slight deceleration, attributed to timing and calendar shifts rather than a decline in customer interest [101][102] Question: International unit growth outlook - Management expressed optimism about international unit growth reacceleration, particularly as closures from Domino's Pizza Enterprises are mostly behind [93][96]

Financial Data and Key Metrics Changes - InMode generated total revenue of $77.9 million in Q1 2025, a decrease of 3% compared to Q1 2024 [8] - GAAP gross margin was 78% in Q1 2025, down from 80% in Q1 2024 [8] - Non-GAAP diluted earnings per share were $0.31, compared to $0.32 in Q1 2024 [12] Business Line Data and Key Metrics Changes - Minimally invasive platforms accounted for 87% of total revenues in Q1 2025 [9] - Sales and marketing expenses decreased slightly to $39.7 million in Q1 2025 from $39.8 million in the same period last year [11] Market Data and Key Metrics Changes - International sales accounted for $38 million or 49% of total sales, a 1% increase compared to Q1 2024 [10] - Europe was the largest revenue contributor from outside the U.S., achieving record sales [10] Company Strategy and Development Direction - The company plans to unveil a new platform for the wellness market later in 2025, aiming to diversify its product offerings [6] - InMode remains committed to maintaining its workforce and not cutting costs, believing this will position the company to lead when market conditions improve [5] Management's Comments on Operating Environment and Future Outlook - Management noted ongoing macroeconomic uncertainty and soft consumer demand affecting the medical aesthetic market [4] - The company anticipates a potential reduction in operating margins by 4% to 5% due to market pressures and U.S. tariffs [13] Other Important Information - InMode completed a share repurchase program, buying back 6.95 million shares for $127 million, returning over $412 million to shareholders in the past year [7] - The company has a strong balance sheet with cash and equivalents totaling $512.9 million as of March 31, 2025 [12] Q&A Session Summary Question: Follow-up on product mix dynamics - Management indicated that the slowdown began in mid-2023 due to rising interest rates and decreased consumer confidence, impacting capital equipment purchases [19] Question: Guidance for Q2 and market recovery - Management expressed optimism for Q2 but noted that if results do not improve significantly, guidance may need to be lowered [30] Question: Impact of tariffs on gross margins - Management explained that current tariffs could impact gross margins by approximately 2% to 3% if they remain at 10% [56] Question: Updates on operating expenses - Management confirmed that they plan to maintain investments in sales and marketing despite macro challenges [63] Question: Pricing strategy in the current market - Management decided against raising prices due to the current market conditions, emphasizing the importance of maintaining competitiveness [70] Question: Performance in Europe compared to the U.S. - Management noted that Europe performed better in Q1 2025, attributed to management changes and pricing strategies [83]

Rithm Property Trust (RPT) Q1 2025 Earnings Call April 28, 2025 05:07 PM ET Speaker0 Thank you for standing by and welcome to the Rhythm Property Trust First Quarter twenty twenty five Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer Thank you. I'd now like to turn the call over to Emma Bola, Associate General Counsel of Rhythm Capital. You may begin. Speaker1 Thank you and good morning everyone. I ...

Financial Data and Key Metrics Changes - The company generated revenue of $665 million in Q1 2025, resulting in 4% organic growth, with a 1% headwind from foreign exchange [27][31] - Adjusted EPS for the quarter was $1.01, exceeding expectations of $0.93 to $0.95 [7][29] - Adjusted operating margins were reported at 25.6%, slightly up year-over-year and above expectations [28] Business Line Data and Key Metrics Changes - Life Sciences segment revenue was $340 million, up 1% reported and 2% organically, with low single-digit growth in pharma biotech customers and a decline in academic and government customers [32] - Diagnostics segment revenue reached $324 million, up 3% reported and 5% organically, driven by high single-digit growth in immunodiagnostics [33] Market Data and Key Metrics Changes - The Americas and Europe experienced mid-single-digit growth, while Asia saw low single-digit growth, with China also growing in low single digits [31] - U.S. academic customers, representing over 5% of total revenue, showed cautious spending due to uncertainties in funding [23][24] Company Strategy and Development Direction - The company is focused on maintaining strong organic growth and operational agility to navigate macroeconomic challenges [5][20] - A recent expanded alliance with Genomics England aims to enhance newborn genomic sequencing capabilities, positioning the company as a leader in this area [9] - The software business, representing about 8% of total revenue, grew over 20% organically in Q1 and is expected to continue strong growth [13][15] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's resilience and ability to adapt to changing market conditions, reaffirming a full-year adjusted EPS outlook of $4.9 to $5 [19][37] - The company anticipates a gross impact of approximately $135 million from tariffs, but expects to mitigate most of this through proactive measures [18][19] Other Important Information - The company repurchased $154 million of its shares in Q1, reducing the outstanding share count to 119.4 million [7][29] - The net debt to adjusted EBITDA leverage ratio was reported at 2.4 times, with all debt being fixed rate [30] Q&A Session Summary Question: Can you talk about the tariff impact and what products are affected? - Management indicated that they have been proactive in adjusting their supply chain to mitigate the $135 million gross tariff impact, focusing on products sold from the U.S. to China [41][43] Question: What are the expectations for the Life Sciences segment? - The Life Sciences segment is expected to see low single-digit growth, with instrumentation under pressure but solid growth in reagents [45][48] Question: How is the company managing its exposure in China? - The company expects low single-digit growth in China, with a slight decline in Life Sciences and mid-single-digit growth in Diagnostics [56] Question: What is the outlook for the software business? - The software business is expected to continue strong double-digit growth, with a focus on expanding into new markets [62][90] Question: What are the long-term margin expectations? - Long-term operating margin expectations remain unchanged, with a focus on SG&A volume leverage as growth continues [104]

Harmonic (HLIT) Q1 2025 Earnings Call April 28, 2025 05:00 PM ET Company Participants David Hanover - Investor RelationsNimrod Ben-Natan - President & CEOWalter Jankovic - Chief Financial OfficerVictor Chiu - Equity Research Associate - Telecom & TechnologyAlyssa Shreves - Vice President - Equity Research Conference Call Participants Steven Frankel - Managing Director, Senior Research AnalystRyan Koontz - Managing Director - Research AnalystTim Savageaux - MD & Senior Research Analyst Operator Welcome to th ...

Financial Data and Key Metrics Changes - Revenue growth accelerated to 40% year over year in Q1 2025, up from 29% in Q4 2024, exceeding previous guidance of 28% to 31% [4][15] - Total revenue for Q1 2025 reached $143 million, with advertising revenue growing 63% and now representing two-thirds of total revenue [5][15] - Adjusted EBITDA was $32 million, with a margin of 23%, indicating increased profitability alongside revenue growth [6][15] Business Line Data and Key Metrics Changes - E-commerce was the fastest-growing vertical within advertising, achieving over 100% annualized growth, which offset typical seasonality [5][15] - Search revenue grew 8% year over year, indicating a slowdown compared to previous growth rates [5][32] - The user base remained stable at 293 million monthly active users (MAUs), with annualized ARPU increasing by 44% [7][15] Market Data and Key Metrics Changes - The U.S. market is experiencing greater uncertainty among advertisers, impacting growth potential [15][21] - The company has less exposure to U.S. e-commerce compared to competitors, suggesting significant growth opportunities ahead [22][63] Company Strategy and Development Direction - The company is focusing on high-value users and leveraging AI to optimize advertising and search revenue [6][10] - Opera is expanding its browser portfolio, including the introduction of AI-driven features, to enhance user experience and engagement [8][10] - The company aims to maintain aggressive growth in e-commerce while navigating macroeconomic challenges [21][63] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's ability to grow despite a volatile macro environment, highlighting a strong track record of navigating challenges [13][21] - The company raised its full-year revenue guidance to DKK 567 million to DKK 582 million, reflecting confidence in continued growth [24][21] - Management noted that the advertising revenue is primarily performance-based, making it more resilient in uncertain economic conditions [22][67] Other Important Information - The company celebrated its 25th anniversary in 2025, emphasizing its long history of innovation and adaptation [13] - Opera has distributed $2.4 in dividends per share since January 2023, indicating a commitment to returning value to shareholders [21] Q&A Session Summary Question: Search growth during the quarter - Management acknowledged that the 8% growth in search revenue is a slowdown but attributed it to a shift towards intent-based advertising, which is driving overall advertising growth [32][34] Question: Decline in GX ARPU - Management noted that the decline in GX ARPU is partly seasonal and that the introduction of AI and high-intent advertising options is expected to benefit overall revenue [32][36] Question: Impact of currency on growth - Management indicated that the strong U.S. dollar has been a headwind, estimating that growth would have been 5 to 6 percentage points higher on a constant currency basis [38] Question: E-commerce growth and seasonality - Management confirmed that the rapid growth of e-commerce has offset typical seasonality, but acknowledged that seasonality will still be a factor as the business matures [41][44] Question: Concerns about MAU count - Management clarified that the focus is on high ARPU users rather than total MAU count, emphasizing revenue generation over user numbers [46][48] Question: U.S. antitrust actions and broader ecosystem - Management expressed that ongoing antitrust discussions could benefit Opera by increasing focus on competition and innovation in the browser market [49][52] Question: E-commerce opportunity and geographic exposure - Management highlighted that the e-commerce segment is growing rapidly and that the U.S. market still holds significant potential for future growth [56][58] Question: Gating factors for e-commerce growth - Management stated that attracting performance-focused advertisers is key to expanding e-commerce revenue, with a focus on larger retailers initially [61][64]

Financial Data and Key Metrics Changes - The company completed a public offering of common stock amounting to $56.5 million to support pipeline growth [5] - Cash and cash equivalents at the end of Q1 2021 were $64.5 million, expected to sustain operations into Q1 2023 [28] - Net loss for Q1 2021 was $8.8 million, an increase from a net loss of $6.5 million in Q1 2020 [28] - Research and development costs rose to $5.6 million in Q1 2021 from $3.8 million in Q1 2020, primarily due to increased headcount and infrastructure expenses [29] - General and administrative expenses increased to $3.1 million in Q1 2021 from $2.8 million in Q1 2020 [30] Business Line Data and Key Metrics Changes - The company initiated the safety lead-in portion of its Phase II trial for MT-401 in post-transplant acute myeloid leukemia (AML), treating the first patient in March 2021 [6][14] - The trial aims to enroll approximately six patients in the safety lead-in, with plans to open around 20 sites for the Phase II portion [15] - MT-401 has shown promising results in prior studies, with a 77% estimated two-year overall survival rate in patients post-infusion [18] Market Data and Key Metrics Changes - The company is focusing on the AML market, where current treatments have limited effectiveness, with only a 25% five-year survival rate for patients [6] - The MultiTAA therapy aims to address tumor heterogeneity and enhance immune response, potentially improving patient outcomes compared to existing therapies [12] Company Strategy and Development Direction - The primary focus for the year is completing the safety lead-in for the AML study and enrolling patients in the Phase II trial [10] - The company is optimizing its MT-401 cell therapy manufacturing process and plans to operationalize a new in-house facility [8] - The strategy includes exploring the application of manufacturing improvements across MultiTAA therapies to increase T cell availability [9] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of MT-401 in the AML patient population based on encouraging preliminary results [20] - The company is committed to addressing the unmet needs in cancer treatment and is exploring additional indications for future development [53] Other Important Information - The company has made significant technical and biological improvements in its manufacturing process, including a 50% reduction in manufacturing time and a 95% decrease in technical interventions [25][26] - The FDA has approved the changes in the manufacturing process, which are currently being implemented in the clinical study [27] Q&A Session Summary Question: Will there be disclosures after the safety lead-in trial? - Management indicated that safety data will be monitored and reported, with potential announcements regarding the main Phase II trial [32][33] Question: Could higher doses of MT-401 be used in the main Phase II trial? - Management confirmed that the new manufacturing process allows for the possibility of higher doses based on previous safety data [36][37] Question: How will manufacturing improvements impact cost and scalability? - Management noted that the simplified manufacturing process is expected to reduce costs and improve yield, making it suitable for future commercialization [43][44] Question: What are the next steps for collaboration with ABB on robotics? - Management expressed excitement about the collaboration, emphasizing the potential for improved consistency in the manufacturing process [49][50] Question: What are the key decision criteria for future indications? - Management highlighted the importance of unmet needs and data-driven decisions for exploring new indications beyond AML [53][54] Question: Update on Baylor's AML trial and higher dose testing? - Management stated that Baylor is nearing completion of the last dose level in their trial, with recent publications providing updates [58][60]

Financial Data and Key Metrics Changes - The company reported revenue from continuing operations of $43.8 million, a decrease from $48.5 million in the same quarter last fiscal year [19] - Net income from continuing operations increased significantly by over 2,000% year over year, reaching RMB3.2 million compared to RMB0.3 million in the same quarter last fiscal year [18][21] - Adjusted net income grew by 179.5% to RMB2.5 million compared to RMB1.3 million for the same quarter last fiscal year [21] Business Line Data and Key Metrics Changes - The schools business accounted for approximately 61% of total revenue, maintaining stable enrollment at 2,699 students year over year [7][9] - Revenue from the overseas study consulting business increased by 6.2% to RMB11.9 million [17][21] - Schools and other revenues were reported at $26.6 million and $5.3 million respectively [21] Market Data and Key Metrics Changes - The company achieved a 14.2% year-over-year improvement in revenue per enrollment at U.S. schools [8] - In the UK, students received offers from eight of the top 10 UK universities, including prestigious institutions like Cambridge and UCL [13][14] Company Strategy and Development Direction - The company is focused on executing a dual engine growth strategy, expanding its school business while enhancing global recruitment efforts [7][15] - There is a commitment to operational efficiency and maintaining high academic standards to drive sustainable long-term value [8][9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to deliver stronger long-term value to students, families, and shareholders, despite macroeconomic headwinds [15] - The company remains optimistic about capitalizing on the growing demand for premier international education [15] Other Important Information - SG&A expenses decreased by 30.7% year over year, improving the SG&A to revenue ratio by 1.2 percentage points [18][21] - The company reported a gross margin from continuing operations of 30%, slightly down from 30.8% in the same quarter last fiscal year [20] Q&A Session Summary - There were no questions during the Q&A session, indicating a lack of immediate inquiries from analysts or investors [23]

Kandi Technologies (KNDI) Q4 2024 Earnings Call April 28, 2025 09:30 AM ET Company Participants Kewa Luo - Manager of Investor Relations Operator As a reminder, this conference is being recorded. I will now turn the conference over to your host, Ms. Kiwa Luo, Investor Relations Manager. Thank you. You may begin. Kewa Luo Thank you, operator. Hello, everyone. Thank you all for joining us on today's conference call to discuss Kandi's results for the full year 2024. Earlier today, we issued a press release cov ...

SuperCom (SPCB) Q4 2024 Earnings Call April 28, 2025 10:00 AM ET Company Participants Ordan Trabelsi - President and CEO Conference Call Participants Matthew Galinko - SVP & Senior Research AnalystGreg Mesniaeff - Research Analyst Operator Ladies and gentlemen, good morning, and welcome to Supercom's Fourth Quarter and Year End twenty twenty four Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen only mode. After today's presentation, there will be an oppo ...